BACKGROUND: Survival rates among childhood cancer survivors (CCS) have enormously increased in the last 40 years. However, this improvement has been achieved at the expense of serious late effects that frequently involve the endocrine system. AIM: To evaluate the cumulative incidence of endocrine diseases in a cohort of long-term CCS. MATERIALS AND METHODS: We analyzed the clinical data of 310 adults, followed for a median time of 16.0 years after the first cancer diagnosis. The monitoring protocols applied to each patient were personalized on the basis of cancer diagnosis and previous treatments, according to the Children's Oncology Group guidelines. RESULTS: The cumulative incidence of endocrine late effects steadily increased over time. At the last follow-up visit available, 48.46% of females and 62.78% of males were affected by at least one endocrine disease. The most common disorders were gonadal dysfunction, primary hypothyroidism, and GH deficiency (GHD). The main risk factors for endocrine disease were male sex (hazard ratio (HR)=1.45, 95% confidence interval (95% CI) 1.05-1.99), radiotherapy (HR=1.91, 95% CI 1.28-2.84), hematopoietic stem cells transplantation (HR=3.11, 95% CI 2.23-4.34), and older age at cancer diagnosis (HR=1.89, 95% CI 1.25-2.85). Male sex was associated with a higher risk of gonadal disorders, whereas radiotherapy specifically increased the risk of GHD and thyroid dysfunction. CONCLUSIONS: Endocrine disorders among CCS have a high prevalence and increase over time. Thus, endocrinologists need to cope with an increasing demand for health care in a field that is still little developed and that, in perspective, could also be extended to some selected types of adult cancer survivors.
BACKGROUND: Survival rates among childhood cancer survivors (CCS) have enormously increased in the last 40 years. However, this improvement has been achieved at the expense of serious late effects that frequently involve the endocrine system. AIM: To evaluate the cumulative incidence of endocrine diseases in a cohort of long-term CCS. MATERIALS AND METHODS: We analyzed the clinical data of 310 adults, followed for a median time of 16.0 years after the first cancer diagnosis. The monitoring protocols applied to each patient were personalized on the basis of cancer diagnosis and previous treatments, according to the Children's Oncology Group guidelines. RESULTS: The cumulative incidence of endocrine late effects steadily increased over time. At the last follow-up visit available, 48.46% of females and 62.78% of males were affected by at least one endocrine disease. The most common disorders were gonadal dysfunction, primary hypothyroidism, and GH deficiency (GHD). The main risk factors for endocrine disease were male sex (hazard ratio (HR)=1.45, 95% confidence interval (95% CI) 1.05-1.99), radiotherapy (HR=1.91, 95% CI 1.28-2.84), hematopoietic stem cells transplantation (HR=3.11, 95% CI 2.23-4.34), and older age at cancer diagnosis (HR=1.89, 95% CI 1.25-2.85). Male sex was associated with a higher risk of gonadal disorders, whereas radiotherapy specifically increased the risk of GHD and thyroid dysfunction. CONCLUSIONS:Endocrine disorders among CCS have a high prevalence and increase over time. Thus, endocrinologists need to cope with an increasing demand for health care in a field that is still little developed and that, in perspective, could also be extended to some selected types of adult cancer survivors.
Authors: Taylor L Morgan; Braedon P Young; Keagan G Lipak; Vicky Lehmann; James Klosky; Gwendolyn P Quinn; Cynthia A Gerhardt; Leena Nahata Journal: J Adolesc Young Adult Oncol Date: 2020-04-22 Impact factor: 2.223
Authors: Wassim Chemaitilly; Qi Liu; Laura van Iersel; Kirsten K Ness; Zhenghong Li; Carmen L Wilson; Tara M Brinkman; James L Klosky; Nicole Barnes; Karen L Clark; Rebecca M Howell; Susan A Smith; Matthew J Krasin; Monika L Metzger; Gregory T Armstrong; Michael W Bishop; Hanneke M van Santen; Ching-Hon Pui; Deo Kumar Srivastava; Yutaka Yasui; Melissa M Hudson; Leslie L Robison; Daniel M Green; Charles A Sklar Journal: J Clin Oncol Date: 2019-09-26 Impact factor: 44.544
Authors: Leena Nahata; Taylor L Morgan; Keagan G Lipak; Olivia E Clark; Nicholas D Yeager; Sarah H O'Brien; Stacy Whiteside; Anthony N Audino; Cynthia A Gerhardt; Gwendolyn P Quinn Journal: J Assist Reprod Genet Date: 2019-08-01 Impact factor: 3.412
Authors: Melissa M Hudson; Matthew J Ehrhardt; Nickhill Bhakta; Malek Baassiri; Hesham Eissa; Wassim Chemaitilly; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Tara M Brinkman; James L Klosky; Kevin R Krull; Noah D Sabin; Carmen L Wilson; I-Chan Huang; Johnnie K Bass; Karen Hale; Sue Kaste; Raja B Khan; Deo Kumar Srivastava; Yutaka Yasui; Vijaya M Joshi; Saumini Srinivasan; Dennis Stokes; Mary Ellen Hoehn; Matthew Wilson; Kirsten K Ness; Leslie L Robison Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-29 Impact factor: 4.254
Authors: E Brignardello; F Felicetti; A Castiglione; N Fortunati; P Matarazzo; E Biasin; C Sacerdote; U Ricardi; F Fagioli; A Corrias; E Arvat Journal: J Endocrinol Invest Date: 2014-10-25 Impact factor: 4.256
Authors: Stacy Tessler Lindau; Emily M Abramsohn; Shirley R Baron; Judith Florendo; Hope K Haefner; Anuja Jhingran; Vanessa Kennedy; Mukta K Krane; David M Kushner; Jennifer McComb; Diane F Merritt; Julie E Park; Amy Siston; Margaret Straub; Lauren Streicher Journal: CA Cancer J Clin Date: 2016-01-19 Impact factor: 508.702
Authors: Leena Nahata; Taylor L Morgan; Keagan G Lipak; Olivia E Clark; Nicholas D Yeager; Sarah H O'Brien; Stacy Whiteside; Anthony Audino; Gwendolyn P Quinn; Cynthia A Gerhardt Journal: Pediatr Blood Cancer Date: 2019-08-12 Impact factor: 3.167
Authors: E Brignardello; F Felicetti; A Castiglione; A Nervo; E Biasin; G Ciccone; F Fagioli; A Corrias Journal: J Cancer Res Clin Oncol Date: 2016-02-10 Impact factor: 4.553
Authors: Wassim Chemaitilly; Zhenghong Li; Sujuan Huang; Kirsten K Ness; Karen L Clark; Daniel M Green; Nicole Barnes; Gregory T Armstrong; Matthew J Krasin; Deo Kumar Srivastava; Ching-Hon Pui; Thomas E Merchant; Larry E Kun; Amar Gajjar; Melissa M Hudson; Leslie L Robison; Charles A Sklar Journal: J Clin Oncol Date: 2015-01-05 Impact factor: 44.544